Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon‐based therapy-Reference-Cited by-同舟云学术

Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon‐based therapy

Published:2022-08-13 Issue:10 Volume:29 Page:899-907
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:Journal of Viral Hepatitis

Author:

Gao Na¹,Yu Huiying¹,Zhang Jing¹^ORCID,Mo Zhishuo¹²³,Chu Junhao¹^ORCID,Xie Chan¹²³,Peng Liang¹²³^ORCID,Gao Zhiliang¹²³

Affiliation:

1. Department of Infectious Diseases Third Affiliated Hospital of Sun Yat‐sen University Guangzhou Guangdong China

2. Guangdong Key Laboratory of Liver Disease Research The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China

3. Key Laboratory of Tropical Disease Control (Sun Yat‐sen University), Ministry of Education Guangzhou Guangdong China

Funder

National Key Research and Development Program of China

Basic and Applied Basic Research Foundation of Guangdong Province

National Natural Science Foundation of China

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13734

Reference23 articles.

1. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2. Hepatitis B virus infection

3. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues

4. The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure

5. HBV cure: why, how, when?

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysis;Hepatology International;2024-03-09

2. Development of a therapeutic monoclonal antibody against circulating adipocyte fatty acid binding protein to treat ischaemic stroke;British Journal of Pharmacology;2023-12-26

3. Editorial:HBsAgseroclearance after pegylated interferon treatment—The beginning of the end. Authors' reply;Alimentary Pharmacology & Therapeutics;2023-10-26

4. Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg‐positive patients with functional cure following PEG‐IFN‐based therapy;Alimentary Pharmacology & Therapeutics;2023-08-29

5. Predictive value of Th17 and Treg cells at baseline for HBsAg loss in chronic hepatitis B patients with low HBsAg quantification treated with pegylated interferon and nucleos(t)ide analogue;Liver Research;2023-06